The Priority Review

Tag

Hepatic Encephalopathy

1 story

  1. Clinical trials

    Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis

    The study, completed in February 2026, enrolled 517 participants and evaluated rifaximin SSD-40mg IR for delaying the first episode of overt hepatic encephalopathy in patients with liver cirrhosis. Results were first posted on ClinicalTrials.gov on October 28, 2026.